Current Status and Treatment of Rapid Cycling Bipolar Disorder

J Clin Psychopharmacol. 2024 Mar-Apr;44(2):86-88. doi: 10.1097/JCP.0000000000001807. Epub 2024 Jan 16.

Abstract

Background: Rapid cycling (RC) at least 4 recurrent episodes per year in bipolar disorder (BD) has been recognized since the 1970s. We now comment on our recent review of the topic and extensive RC analysis in a large clinical cohort, emphasizing therapeutics research.

Comments: Prevalence of RC-BD averages 36% for any year versus 22% in the preceding year. Rapid cycling is not a consistent feature over many years, although average long-term, annual recurrence rates are greater in RC-BD patients. Risk of RC may be somewhat greater among women and with older ages. It is also associated with cyclothymic temperament, prominent depression, and mood-switching with antidepressant treatment and is associated with increased suicidal risk. Treatment of individual episodes in RC-BD and effective long-term prevention remain inadequately studied, although antidepressant treatment can worsen RC. Some research supports treatment with aripiprazole, lamotrigine, and lithium, and interest in second-generation antipsychotics is emerging. All such options are used in various inadequately evaluated combinations.

Conclusions: Rapid cycling is prevalent among BD patients but seems to vary in risk over time without evidence of progressive worsening. Treatment of acute episodes in RC-BD patients and effective long-term preventive management require much more intensive investigation.

MeSH terms

  • Anticonvulsants / therapeutic use
  • Antidepressive Agents / therapeutic use
  • Antipsychotic Agents* / adverse effects
  • Bipolar Disorder* / epidemiology
  • Female
  • Humans
  • Lithium / therapeutic use

Substances

  • Antipsychotic Agents
  • Antidepressive Agents
  • Lithium
  • Anticonvulsants